A meta-analysis of 29 trials (1,529 women) found weight loss interventions — including GLP-1 agonists — significantly improved insulin resistance, reduced excess androgens, and restored menstrual frequency in women with PCOS.
+2.64 menstrual cyclesWeight loss interventions including GLP-1 agonists significantly increased menstrual frequency in women with PCOS, addressing one of the condition's most impactful symptoms
What the researchers found
Weight loss interventions significantly improved HOMA-IR (-0.45, CI -0.75 to -0.15), free androgen index (-2.03, CI -3.0 to -1.07), and menstrual frequency (+2.64, CI 0.65-4.63). Nine trials used GLP-1 agonists. No significant effect on hirsutism or quality of life. Published in Annals of Internal Medicine.
Why it matters
PCOS affects 8-13% of women of reproductive age and is closely linked to obesity. While guidelines recommend weight loss, this is the most comprehensive evidence to date showing which PCOS features actually improve — and which don't — validating weight loss as a core PCOS treatment strategy.
The numbers in context
Databases searched from inception through June 2024. RCTs comparing weight loss interventions to usual care in PCOS.
How the study worked
Systematic review and meta-analysis. Searched MEDLINE, Embase, PsycINFO, CINAHL, Cochrane, and Web of Science through June 2024. Included RCTs comparing weight loss interventions to usual care in PCOS. 29 comparisons, 1,529 participants. Random-effects meta-analysis with Knapp-Hartung adjustment. Risk of bias assessed for each study.
Who was studied
Women with PCOS from randomized controlled trials
What this study cannot tell us
High statistical heterogeneity across interventions and comparators. Most studies had high or some risk of bias. GLP-1 trials not analyzed separately in the primary analysis. No evidence of hirsutism or QoL improvement, though may be due to limited power. Short study durations may miss long-term benefits.
How to read the evidence
Rated strong: systematic review and meta-analysis of 29 RCTs, published in Annals of Internal Medicine with PROSPERO registration. Limited by heterogeneity and variable risk of bias in included studies.
When this study was published
Published in 2024. The most comprehensive meta-analysis to date on weight loss interventions for PCOS symptoms.
The bigger picture
With GLP-1 peptide drugs producing unprecedented weight loss, this meta-analysis provides the evidence base for deploying these medications specifically for PCOS. The finding that weight loss restores menstrual cycles and reduces androgens could reshape PCOS management toward metabolic-first approaches.
Questions still open
- Do GLP-1 agonists specifically improve PCOS outcomes beyond their weight loss effect?
- How much weight loss is needed to achieve meaningful improvements in menstrual frequency and androgen levels?
- Would longer treatment durations show improvements in hirsutism and quality of life?
Common questions
Can losing weight help with PCOS symptoms?
Can GLP-1 drugs like semaglutide help with PCOS?
Read the original research
Effect of Weight Loss Interventions on the Symptomatic Burden and Biomarkers of Polycystic Ovary Syndrome : A Systematic Review of Randomized Controlled Trials.
Annals of internal medicine, 177(12), 1664-1674
Citation
Scragg, Jadine; Hobson, Alice; Willis, Lia; Taylor, Kathryn S; Dixon, Sharon; Jebb, Susan A. (2024). Effect of Weight Loss Interventions on the Symptomatic Burden and Biomarkers of Polycystic Ovary Syndrome : A Systematic Review of Randomized Controlled Trials.. Annals of internal medicine, 177(12), 1664-1674. https://doi.org/10.7326/M23-3179